Investigation of intravenous delivery of nanoliposomal topotecan for activity against orthotopic glioblastoma xenografts

Neuro-Oncology

Volumn 13, Issue 12, 2011, Pages 1288-1295

  Serwer, Laura P ^a,b   Noble, Charles O ^c   Michaud, Karine ^a   Drummond, Daryl C ^c   Kirpotin, Dmitri B ^c   Ozawa, Tomoko ^a   Prados, Michael D ^a   Park, John W ^b   James, C David ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MERRIMACK PHARMACEUTICALS   (United States)

Author keywords

Bioluminescence imaging; Glioma; Liposome; Topotecan; Xenograft.

Indexed keywords

CASPASE 3; TOPOTECAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG FORMULATION; GLIOBLASTOMA; MOUSE; NONHUMAN; TUMOR XENOGRAFT;

ANIMALS; BRAIN NEOPLASMS; DRUG DELIVERY SYSTEMS; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOENZYME TECHNIQUES; LIPOSOMES; LUMINESCENT MEASUREMENTS; MICE; MICE, NUDE; NANOTECHNOLOGY; SURVIVAL RATE; TISSUE DISTRIBUTION; TOPOISOMERASE I INHIBITORS; TOPOTECAN; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863011929     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nor139     Document Type: Article

References (40)

1. Bookman MA, Malmstrom H, Bolis G, et al. Topotecan for the treatment of advanced epithelial ovarian cancer: An open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol. 1998;16: 3345-3352. (Pubitemid 28481631)
2. Depierre A, von Pawel J, Hans K, et al. Evaluation of topotecan (Hycamtin) in relapsed small cell lung cancer (SCLC). A multicentre phase II study. Lung Cancer. 1997;18(suppl 1):35.
3. ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan vs paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol. 1997;15:2183-2193. (Pubitemid 27251118)
4. ten Bokkel Huinink W, Lane SR, Ross GA, the International Topotecan Study Group. Long-term survival in a phase III, randomised study of topotecan vs paclitaxel in advanced epithelial ovarian carcinoma. Ann Oncol. 2004;15:100-103. (Pubitemid 38139610)
5. Ciusani E, Croci D, Gelati M, et al. In vitro effects of topotecan and ionizing radiation on TRAIL/Apo2L-mediated apoptosis in malignant glioma. J Neuro-Oncol. 2005;71:19-25. (Pubitemid 40277248)
6. Rapisarda A, Zalek J, Hollingshead M, et al. Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res. 2004;64:6845-6848. (Pubitemid 39330988)
7. Baker SD, Heideman RL, Crom WR, et al. Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors. Cancer Chemother Pharmacol. 1996;37:195-202.
8. Macdonald D, Cairncross G, Stewart D, et al. Phase II study of topotecan in patients with recurrent malignant glioma. National Clinical Institute of Canada Clinical Trials Group. Ann Oncol. 1996;7(2):205-207. (Pubitemid 26094886)
9. Friedman HS, Kerby T, Fields S, et al. Topotecan treatment of adults with primary malignant glioma. The Brain Tumor Center at Duke. Cancer. 1999;85(5):1160-1165. (Pubitemid 29115597)
10. Blaney SM, Phillips PC, Packer RJ, et al. Phase II evaluation of topotecan for pediatric central nervous system tumors. Cancer. 1996;78(3):527-531. (Pubitemid 26250540)
11. Mi Z, Malak H, Burke TG. Reduced albumin binding promotes the stability and activity of topotecan in human blood. Biochemistry. 1995;34(42):13722-13728.
12. Tardi P, Choice E, Masin D, Redelmeier T, Bally M, Madden TD. Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models. Clin Cancer Res. 2001;60:3389-3393. (Pubitemid 30482152)
13. Drummond DC, Noble CO, Guo Z, et al. Development of a highly stable and targetable nanoliposomal formulation of topotecan. J Control Release. 2010;141(1):13-21.
14. Saito R, Krauze MT, Noble CO, et al. Convection-enhanced delivery of Ls-TPT enables an effective continuous, low dose chemotherapy against malignant glioma xenograft model. Neuro Oncol. 2006;8(3):205-214. (Pubitemid 46542645)
15. Burke TG, Gao X. Stabilization of topotecan in low pH liposomes composed of distearoylphosphatidylcholine. J Pharm Sci. 1994;83: 967-969. (Pubitemid 24228546)
16. Tardi P, Choice E, Masin D, Redelmeier T, Bally M, Madden TD. Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models. Clin Cancer Res. 2000;60: 3389-3393. (Pubitemid 30482152)
17. Dinca EB, Sarkaria JN, Schroeder MA, et al. Bioluminescence monitoring of intracranial glioblastoma xenograft: Response to primary and salvage temozolomide therapy. J Neurosurg. 2007;108(3):610-616. (Pubitemid 47451046)
18. Bartlett GR. Phosphorus assay in column chromatography. J Biol Chem. 1959;234(3):466-468.
19. Roland M, Tozer T. Clinical Pharmacokinetics: Concepts and Applications. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 1995.
20. UCSF Animal Care and Use Program. Standard Procedures and Guidelines. http://www.iacuc.ucsf.edu/Policies/awStandard Procedures.asp. Accessed June 9, 2011.
21. Serwer L, Hashizume R, Ozawa T, James CD. Systemic and local drug delivery for treating diseases of the central nervous system in rodent models. J Vis Exp. 2010;42. http://www.jove.com/Details. php?ID=1992.
22. Sarkaria JN, Yang L, Grogan PT, et al. Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. Mol Cancer Ther. 2007;6:1167-1174. (Pubitemid 46554588)
23. Giannini C, Sarkaria JN, Saito A, et al. Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro Oncol. 2005;7(2):164-176. (Pubitemid 40590516)
24. Verhaak RG, Hoadley KA, Purdom E, et al. Cancer Genome Atlas Research Network. Intergrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98-110.
25. Michaud K, Solomon DA, Oermann E, et al. Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Res. 2010;70(8): 3228-3238.
26. Quinn JA, Jiang SX, Reardon DA, et al. Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy. J Neuro-Oncol. 2009;95(3): 393-400.
27. Drummond DC, Noble CO, Guo Z, Hong K, Park JW, Kirpotin DB. Development of a Highly Active Nanoliposomal Irinotecan Using a Novel Intraliposomal Stabilization Strategy. Cancer Res. 2006;66: 3271-3277.
28. Allen TM, Cullis PR. Drug delivery systems: Entering the mainstream. Science. 2004;303:1818-1822. (Pubitemid 38374867)
29. Drummond DC, Meyer O, Hong KL, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev. 1999;51:691-743.
30. Drummond DC, Noble CO, Hayes ME, Park JW, Kirpotin DB. Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. J Pharm Sci. 2008;97(11):4696-4740.
31. Dickinson PJ, LeCouteur RA, Higgins RJ, et al. Canine model of convection-enhanced delivery of liposomes containing CPT-11 monitored with real-time magnentic resonance imaging: Laboratory investigation. J Neurosurg. 2008;108(5):989-998. (Pubitemid 351656848)
32. Noble CO, Krauze MT, Drummond DC, et al. Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: Pharmacology and efficacy. Cancer Res. 2006;66(5): 2801-2806.
33. Saito R, Bringas JR, McKnight TR, et al. Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging. Cancer Res. 2004;64: 2572-2579. (Pubitemid 38523915)
34. Mamot C, Nguyen JB, Pourdehnad M, et al. Extensive distribution of liposomes in rodent brains and brain tumors following convectionenhanced delivery. J Neuro-Oncol. 2004;68:1-9. (Pubitemid 39137344)
35. Sampson JH, Akabani G, Archer GE, et al. Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro Oncol. 2008;10(3):320-329.
36. Yamashita Y, Krauze MT, Kawaguchi T, et al. Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts. Neuro Oncol. 2007;9(1): 20-28. (Pubitemid 46543485)
37. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med. 2005;353:2012-2024. (Pubitemid 41609094)
38. Neuhaus T, Ko Y, Muller RP, et al. A phase III trial of topotecan and whole brain radiation therapy for patients with CNS-metastases due to lung cancer. Br J Cancer. 2009;100(2):291-297.
39. Fisher B, Won M, Macdonald D, Johnson DW, Roa W. Phase II study of topotecan plus cranial radiation for glioblastoma multiforme: Results of Radiation Therapy Oncology Group 9513. Int J Radiat Oncol Biol Phys. 2002;53(4):980-986. (Pubitemid 34722645)
40. Paik PK, Rudin CM, Brown A, et al. A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies. Cancer Chemother Pharmacol. 2010;66:1079-1085.